Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. It also advancing the development of Psilocybin-based therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).


CSE:RVV - Post by User

Comment by Trippedstockson Nov 16, 2021 12:12pm
129 Views
Post# 34132269

RE:RE:RE:Nothing but up from here folks!!

RE:RE:RE:Nothing but up from here folks!!
from Feb 25, 2021 MD&A

(3) The Companys discovery and formulation development programs includes exploring novel uses of Bucillamine for infectious diseases, liver diseases, and other psychedelic compounds for various disorders in pre-clinical models. The Company is pursuing the development of a next generation formulation of Bucillamine. The $2,000,000 is anticipated to be allocated to cover the following milestones and activities for the discovery research and formulation development: (i) complete pre- clinical research of Bucillamine in various in-vitro and in-vivo models targeting infectious diseases and respiratory disorders under a research agreement with academic research laboratories or clinical research organizations ($500,000); (ii) complete pre-clinical research with DMT, MDMA and LSD in various in-vitro and in-vivo models targeting various neurological disorders under a research agreement with academic research laboratories or clinical research organizations ($500,000) and (iii) conduct reformulation development program with Bucillamine with the aim to improve the oral bioavailability and generate new intellectual property ($1,000,000).
<< Previous
Bullboard Posts
Next >>